Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.995
-0.045 (-2.21%)
Dec 26, 2025, 9:56 AM EST - Market open
Opus Genetics Employees
Opus Genetics had 18 employees as of December 31, 2024. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
$812,944
Profits / Employee
-$3,789,056
Market Cap
137.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 4 | 28.57% |
| Dec 31, 2023 | 14 | 5 | 55.56% |
| Dec 31, 2022 | 9 | 1 | 12.50% |
| Dec 31, 2021 | 8 | 3 | 60.00% |
| Dec 31, 2020 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IRD News
- 9 days ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 17 days ago - Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease - GlobeNewsWire
- 5 weeks ago - Opus Genetics to Participate in Upcoming Investment Conferences - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease - GlobeNewsWire
- 6 weeks ago - Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces $23 Million Registered Direct Offering - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease - GlobeNewsWire